The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)

Table 2 Multivariate Cox regression analysis of PFS and OS

Characteristics	PFS		OS
Characteristics	Hazard ratios (95%CI)	P value	Hazard ratios (95%CI)	P value
Age (year)
≤ 45	1.0
> 45	1.558 (1.054–2.302)	0.026*
Menopausal status
Premenopausal	1.0
Postmenopausal	0.745 (0.438–1.270)	0.280
Number of metastatic sites
< 2	1.0		1.0
≥ 2	1.679 (1.151–2.450)	0.007*	1.691 (1.087–2.630)	0.020*
Brain metastases
No	1.0		1.0
Yes	1.582 (1.019–2.453)	0.041*	1.833 (1.133–2.963)	0.013*
Duration of prior trastuzumab treatment
< 6 months			1.0
≥ 6 months			0.863 (0.546–1.364)	0.528

^*P < 0.05
^aMetastases in lung/liver
Abbreviation: PFS Progression-Free Survival, OS Overall Survival, CI Confidence Interval

ISSN: 1471-2407